Search
Investors Overview

Driving value for our business, our investors, and global health.

About MedMira Inc.

Since our founding in 1993, MedMira has focused on advancing rapid diagnostics through innovation, reliability, and speed. We develop, manufacture, license, and market high-quality rapid testing solutions built on our patented Rapid Vertical Flow Technology™, a flow-through platform that delivers fast, accurate results across diverse health and safety applications.

MedMira became a publicly traded company in 2000, and our stock is listed on the TSX Venture Exchange under MIR, with additional access for U.S. investors through MMIRF. Headquartered in Halifax, Nova Scotia, we continue to strengthen our position in the global diagnostics market by providing technologies that empower faster decisions, better outcomes, and broader market opportunities.

MedMira was built as a platform company from the beginning. Rapid Vertical Flow established our leadership in ultra-fast, reliable point-of-care testing. Today, multiplexing expands our menu, and MiROQ™ moves us into quantitative diagnostics – opening entirely new clinical and commercial markets. This evolution positions MedMira not just as a test developer, but as a long-term technology leader in decentralized diagnostics.

Hermes Chan, D.Sc. (h.c.)

CEO, Co-Founder and Co-Inventor of MedMira Inc.

 

Latest reports

Contacts

Investor Relations

Phone: 902 450 1588
T/F. 877 633 6372
E-Mail: ir@medmira.com

Transfer Agent

Computershare
1500 Robert-Bourassa Blvd., 7th Floor
Montreal, Quebec H3A 3S8
Phone: 902 482 0486
www.computershare.com

Frequently Asked Questions

Explore concise answers to frequent investor inquiries.

When does MedMira’s fiscal year end?

MedMira’s fiscal year ends July 31.

When does MedMira plan to announce quarterly financial results?

MedMira releases quarterly financial results within 60 days of the quarter ending.

When does MedMira plan to announce annual financial results?

MedMira releases annual financial results within 120 days of the fiscal year ending.

Who can I contact with questions regarding my stock certificates?

For shareholder inquiries regarding stock certificates, change of address, transfer of ownership or other stock account matters, please contact our transfer agent, Computershare Trust Company of Canada at TF. 1 800 564 6253 (in Canada and the United States) or 514 982 7555 (international direct dial) between the hours of 8:30 am and 8:00 pm EST.

Who are MedMira’s independent auditors?

Arsenault Best Cameron Ellis,Chartered Professional Accountants & Business Advisors

18 Queen Street, Suite 100, P. O. Box 455
Charlottetown, PE C1A 7L1
T. 902 368 3100
www.acgca.ca

Where is MedMira’s corporate headquarters?

Computershare

1500 Robert-Bourassa Blvd., 7th Floor
Montreal, Quebec H3A 3S8
T. 1 902 482 0486
www.computershare.com

Explore further

Learn about the products and platforms driving our next stage of growth.

Discover our global partners driving innovation and market expansion.

Get to know the company behind our innovative rapid testing solutions.

Privacy Policy

Last updated: April 20, 2026

MedMira Inc. (“MedMira”, “we”, “us”, or “our”) is committed to protecting personal information in accordance with applicable privacy laws, including the Personal Information Protection and Electronic Documents Act (PIPEDA) in Canada, as well as applicable United States and international privacy requirements.

This Privacy Policy describes how we collect, use, disclose, and safeguard personal information through our website. Our website is primarily informational in nature and does not provide user accounts, applications, or diagnostic services.

Terms And Conditions Of Use

Please Read These Terms Carefully Before Using This Site. This website is provided by MedMira Inc. (MedMira) and may be used for informational purposes only. By using the site or downloading materials from the site, you agree to abide by the terms and conditions set forth in this notice. If you do not agree to abide by these terms and conditions do not use the site or download materials from the site.

Subscribe
Join our newsletter

Receive company updates, regulatory milestones, and event announcements.

By subscribing, you agree to our Privacy Policy and consent to receive updates.

Committed to quality
Certified & Proven Quality

Our quality management system is ISO 13485:2016 certified, compliant with the United States Food and Drug Administration’s current Good Manufacturing Practices (cGMP: Quality System Regulation Part 820 of CFR Title 21, Volume 8), European Union’s Directive 98/79/EC on in vitro diagnostic medical devices, and Health Canada Medical Device Regulations (SOR/98-282).

Additionally, we adhere to ISO 14971 (Application of Risk Management to Medical Devices) and ISO 2859 (Sampling Procedures for Inspection by Attributes). Certification and compliance to these requirements attests to our ability to maintain the highest standard of quality in medical device manufacturing, product development and corporate conduct.

Our products have been approved by regulators and UN agencies worldwide.

FDA

Health Canada

International Trade Centre (ITC)

Pan American Healtch Organization (PAHO)

UN Development Programme (UNDP)

UN Office for Project Services (UNOPS)

UN Office at Vienna (UNOV)

UN Population Fund (UNFPA)

United States Agency for International Development (USAID)

CFO & Head of Commercialization

Markus Meile

Markus joined MedMira in 2010, and moved into the role of Chief Financial Officer in 2014.

He previously served on the Company’s Board of Directors, as a member of the Audit Committee, and as the Senior Director of International Markets.

Prior to joining MedMira, Markus worked with a number of financial institutions in Switzerland, England, and Hong Kong. He holds a BSc from Royal Holloway University of London and has studied business management, strategic planning, investment and accounting at business school in Zurich. Previously, Markus worked in the medical device industry in Africa, Asia Pacific, and Europe.

He will combine his financial expertise with his broad range of international business knowledge to build financial and corporate strategies supporting MedMira’s continuing growth and increasing shareholder value.

Director of the Audit Committee, Nomination and Compensation Committee

Jianhe Mao

Jianhe Mao is the owner of Unipec, a consulting firm based in St. Gallen, Switzerland. Unipec focuses on helping European companies enter the Chinese market, through operational restructuring and ownership and management optimization.

In addition to leading Unipec, Mr. Mao is involved in several industrial projects and start-up ventures including Monsatec AG, a new company bridging the gap between laboratories and clinics with a cold plasma medical device. He serves on the boards of several European companies and is regarded as a trusted expert in legal cases, corporate corruption, operational turnarounds, and mergers and acquisitions.

Mr. Mao began his career as a project engineer and has gained experience in business development and real estate investment. He holds M.E. from Ruhr University Bochum.

CEO, Co-Founder & Co-Inventor

Hermes Chan, D.Sc. (h.c.)

Hermes Chan, our Chief Executive Officer and Co-Founder, leads our passionate and committed team in driving the strategic direction and growth of MedMira.

Hermes, who was named BioScience Innovator of the Year by The Economist in 2007, is the inventor of our patented rapid flow-through diagnostic technology platform.

Since the company’s inception in 1994 Hermes has held progressively senior management roles including Research Scientist, General Manager, Senior Vice President, and Chief Operating Officer.

Prior to creating MedMira, Hermes worked with another Canadian biotechnology company in the diagnostics research sector.

Chair member of the Audit Committee, Nomination and Compensation Committee

Steven Cummings

Mr. Steven Cummings is the Founder & President of Cambridge Financial Services, one of the leading full service accounting, tax, and business advisory firms in Nova Scotia.

Under Mr. Cummings leadership, Cambridge Financial has earned an enviable reputation among businesses and industry for a commitment to high standards. Along with his leadership responsibilities at Cambridge Financial Services, Mr. Cummings was engaged as MedMira’s interim Chief Financial Officer in 2007.

With more than 30 years of financial and entrepreneurial experience, Mr. Cummings is a frequent guest speaker on issues surrounding provincial taxation, taxation of seniors, and business ownership

Intellectual property

China

ZL02819646.5

Rapid Diagnostic Device and Assay

Intellectual property

European union

EP1417489

Rapid Diagnostic Device and Assay

EP1328811

HCV Mosaic Antigen Composition (2021)

Intellectual property

USA

9,164,087

Rapid Diagnostic Device, assay and multifunctional Buffer

9,086,410

Downward or vertical flow diagnostic device and assay

8,025,850

Rapid Diagnostic Device, Assay and Multifunctional Buffer

8,287,817

Rapid Diagnostic Device, Assay and Multifunctional Buffer

8,586,375

Rapid Diagnostic Device, Assay and Multifunctional Buffer

7,531,362

Rapid Diagnostic Device, Assay and Multifunctional Buffer

D706945

Diagnostic Device

D706466

Diagnostic Device

11,353,450

Analyte Detection Using Raman Spectroscopy

Intellectual property

Canada

CA2,493,616

Rapid Diagnostic Device, Assay and Multifunctional Buffer

CA2,740,902

Downward or Vertical Flow Diagnostic Device and Assay

CA2,949,634

Analyte Detection Using Raman Spectroscopy

MiROQ Vision

Handheld Device

A future concept built on the same MIROQ technology, designed to deliver lab-grade precision in the palm of your hand.

We envision a future where testing can happen anywhere, anytime – from hospitals and clinics to remote regions or even at home – enabling early disease detection and turning knowledge into real impact. No large equipment or complex infrastructure required.

For: Doctor’s offices, small and mobile clinics

Future application: Home use

Connectivity: Bluetooth, Wifi and USB